Navigation Links
Kendle Announces New Revolving Credit Facility
Date:3/17/2010

CINCINNATI, March 17 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that it has entered into a new $35 million secured revolving credit facility as of March 15, 2010 with JPMorgan Chase Bank N.A., as administrative agent, which replaces the Company's previous revolving credit facility. The new facility contains provisions allowing the Company to request an increase of up to $15 million in capacity, subject to the consent of the current lender or additional lenders.  The new revolving facility matures on January 15, 2012 and is automatically extended to March 31, 2015 if certain conditions are met related to the Company's convertible notes.  

Commenting on the transaction, Keith Cheesman, Senior Vice President and Chief Financial Officer said, "We are very pleased with this new facility and with having JPMorgan Chase serve as our agent.  This new facility offers more flexible terms and conditions, together with a duration and a capacity, all of which will better position us to execute against our long-term strategic plans."

Under the terms of this new facility, the Company may borrow in U.S. dollars or other globally-traded currencies, including the Euro and the Pound Sterling. The new credit agreement contains various affirmative and negative covenants including limitations on capital expenditures, investments, indebtedness, acquisitions and asset sales outside the ordinary course of business.  The new agreement also contains various financial covenants including a total leverage ratio, a senior leverage ratio and an interest coverage ratio.  Additional details about the new credit facility are available in the Company's most recently filed Annual Report on Form 10-K.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.

Forward-Looking Statements

Certain statements and information contained in this press release may be deemed to be forward-looking statements under federal securities laws and the provisions of the Private Securities Litigation Reform Act of 1995 and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. All such forward-looking statements, including the statements contained herein regarding anticipated benefits of the new revolving credit facility, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC.  All information in this press release is current as of March 17, 2010. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

SOURCE Kendle International Inc.

Back to top

RELATED LINKS
http://www.kendle.com

'/>"/>

SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
2. Kendle to Present at UBS Global Life Sciences Conference
3. Kendle to Present at Robert Baird 2009 Health Care Conference
4. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
5. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
6. Kendle Names Jarrod Pontius Chief Legal Officer
7. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
8. Kendle Announces First Quarter 2009 Results
9. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
10. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
11. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS ... the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US ... absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):